Journal
JOURNAL OF CROHNS & COLITIS
Volume 12, Issue -, Pages S653-S668Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjy060
Keywords
Vedolizumab; etrolizumab; natalizumab; abrilumab; alpha 4 beta 7; alpha E; alpha E beta 7; CD103; CD49d; alpha L beta 2; LFA-1; integrin; lymphocyte; leukocyte; trafficking; inflammatory bowel disease; IBD; ulcerative colitis; UC; Crohn's disease; CD; MAdCAM-1; VCAM-1; ICAM-1; AJM300; carotegrast methyl; PTG-100; HIV; human immunodeficiency virus
Categories
Funding
- National Institute for Health Research [NIHR]
Ask authors/readers for more resources
Integrins are cell surface receptors with bidirectional signalling capabilities that can bind to adhesion molecules in order to mediate homing of leukocytes to peripheral tissues. Gut-selective leukocyte homing is facilitated by interactions between alpha 4 beta 7 and its ligand, mucosal addressin cellular adhesion molecule-1 [MAdCAM-1], while retention of lymphocytes in mucosal tissues is mediated by alpha E beta 7 binding to its ligand E-cadherin. Therapies targeting gut-selective trafficking have shown efficacy in inflammatory bowel disease [IBD], confirming the importance of leukocyte trafficking in disease pathobiology. This review will provide an overview of integrin structure, function and signalling, and highlight the role that these molecules play in leukocyte homing and retention. Anti-integrin therapeutics, including gut-selective antibodies against the beta 7 integrin subunit [etrolizumab] and the alpha 4 beta 7 integrin heterodimer [vedolizumab and abrilumab], and the non-gut selective anti-alpha 4 integrin [natalizumab], will be discussed, as well as novel targeting approaches using small molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available